The immunotherapy drugs market size to reach USD 512.1 Billion by 2032 at 10.4% CAGR during the forecast period 2023 and 2032, reveals Market Research Future (MRFR). Immunotherapy is a form of cancer treatment that can boost the body's natural immune system. so that the body will be ready to fight cancer cells. The therapy uses the things made by the organisation or in vitro in the laboratory. Several types of Immunotherapy work in different mechanisms.
Several immunotherapy treatments can stop the growth of cancer cells. Other therapies aid the immune system in eliminating the cancer cells and help the body from spreading to other parts of the body. Immunotherapy treatments can be used either alone or combined with other cancer treatments. These drugs are used to improve the immune system of the body. This is used in other therapies but mostly for cancer treatments.
Antibodies produced against antigens kill the cancerous or tumour cells. Several factors drive the market, and some of them are increasing the adoption of targeted therapies and improvement of the lifespan of people are some of the major elements of the market. The rise of cancer patients and continuous evaluation for safety and quality will boost the market. The factors that can hinder the market are the high cost of manufacturing the drugs used in the treatment, and side effects related to this will decline the market growth.
The Immunotherapy Drugs market is segmented based on therapy area, type of drugs, end user and region.
On the basis therapy area, the market of immunotherapy drugs is segmented into cancer, autoimmune & inflammatory diseases, infectious diseases and others. Further, on the basis of type of drugs the market of immunotherapy drugs is segmented into Monoclonal Antibodies, Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha & Beta, Interleukins and Others. Further end user is segmented into hospitals & clinics, ambulatory surgical centers, others.
Immunotherapy drugs market is segmented into four main geographical region, they are Americas, Europe, Asia Pacific and The Middle East and Africa.
Over the last few years, Americas and Europe are the major contributors in the market of immunotherapy drugs. Due to their reputation as a suitable place for research and development. The immunotherapy drugs market has a huge demand in both region and is expected to grow in coming future.
Asia Pacific is however the fastest growing market immunotherapy drugs owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure.
Moreover increasing demand for new treatment methods in countries like India and South Korea are likely to emerge as the fastest growing market across the globe.
The Middle East and Africa holding the least growth in comparison to other region, although, increasing occurrence of cancer owing to smoking, change in lifestyle, and excessive alcohol intake are driving the immunotherapy drugs market in this region.
Recent Development
November 2023: Bristol Myers Squibb receives FDA approval for its Opdivo (nivolumab) immunotherapy drug for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The approval is based on data from the Phase III CheckMate 358 trial, which showed that Opdivo significantly improved overall survival compared to chemotherapy in patients with recurrent or metastatic HNSCC.Roche receives FDA approval for its Tecentriq (atezolizumab) immunotherapy drug for the treatment of unresectable or metastatic locally advanced non-small cell lung cancer (NSCLC). The approval is based on data from the Phase III IMpower150 trial, which showed that Tecentriq significantly improved overall survival compared to chemotherapy in patients with unresectable or metastatic locally advanced NSCLC.Merck announces that its Keytruda (pembrolizumab) immunotherapy drug has demonstrated significant efficacy in the treatment of patients with advanced Merkel cell carcinoma (MCC). The data, presented at the European Society for Medical Oncology (ESMO) 2023 Congress, showed that Keytruda resulted in an overall response rate of 54% and a median overall survival of 12.6 months in patients with MCC.
September 2023: Several companies announce new partnerships to develop and commercialize new immunotherapy drugs and technologies. These partnerships aim to develop new therapies for a variety of diseases, including cancer, autoimmune diseases, and infectious diseases.A new study published in the journal Nature Medicine finds that a combination of two immunotherapy drugs can effectively treat patients with advanced melanoma. The study found that the combination of Keytruda and Tecentriq resulted in an overall response rate of 83% and a median overall survival of 24.6 months in patients with advanced melanoma.Another study published in the journal Cell Stem Cell finds that a new type of immunotherapy drug can be used to treat type 1 diabetes. The study found that the drug was effective in producing insulin in the body and reversing the symptoms of diabetes.
May 2022: The Food and Drug Administration, also called FDA, grants Priority Review to applications for medicines. If the offer gets approved, it will offer significant improvements over available options by demonstrating safety or efficacy improvements. It will also prevent serious conditions or enhance patient compliance.
Rakuten Medical develops photo immunotherapies using its Alluminox platform, which consists of a drug, a device, and other related technologies. The drug component of the platform contains a cancer-cell-targeting moiety that is conjugated with one or more dyes. The device component, a source of nonthermal light, transiently activates the drug, instigating a biophysical process that disrupts the membranes of targeted cells and causes rapid necrosis.
A beneficial cancer vaccine developed by MIT scientists concentrates on the STING pathway, essential for the immune system's reaction to cancer cells. In mouse models of various cancers, this vaccine has demonstrated significant promise in removing tumors, preventing metastasis, and preventing recurrence—all with minimal side effects. Even when the STING gene has been altered, the remedy still works. The study also exposed a previously unknown crucial function of CD4+ T cells in antitumor immunity. Researchers have developed various combination therapy strategies to conquer resistance to the blockade of checkpoint therapies, with the STING pathway as one of the most alluring research areas. In a mouse model of breast cancer, the vaccine also reduced metastasis and shielded cured mice from tumor recurrence. Given that it plays a crucial part in enhancing the immune system's reaction to infectious agents and cancer cells, the STING pathway shows promise as a companion for immune checkpoint-blocking therapies.
Northwestern Medicine researchers have created a biomarker signature examination to identify tumors that will respond to immunotherapy, a development that could increase the survival of patients with bladder cancer. Only approximately twenty percent of bladder cancers respond well to checkpoint immunotherapy medication, which prompts the immune system to detect a tumor. However, clinicians are unaware of which patients will benefit and why some may not benefit more. Researchers from Northwestern University Feinberg School of Medicine identified three types of tumors that might respond to immunotherapy and two that could not in the new study, which involved numerous international collaborators. The researchers also examined the non-responsive cancers to find interesting new therapies and medications that might make them adaptable to immunotherapy using an amalgam of gene expression profiling, mutations, and spatial proteomics.
Immunotherapy Drugs Market Share (%), by Region
Sources: Centers for Disease Control and Prevention, U.S. Census Bureau, Kodiak Island Borough School District Annual Reports, Press Release, White Paper, And Company Presentation
Research Methodology
Market Research Future research is conducted by industry experts who offer insights into industry structure, market segmentation, assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analysing historical market trends and current position of immunotherapy drugs. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.
Extensive primary research was conducted to gain a deeper insight of the market and the industry performance. In this particular report we have conducted primary surveys (interviews) with key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of major players who are active in the immunotherapy drugs market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.
Secondary research was mainly used to collect and identify information useful for extensive, technical, market-oriented, and commercial study of the Immunotherapy Drugs market. It was also used to obtain key information about major players, market classification, and segmentation according to industry trends, geographical markets, and developments related to the market and perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company web sites, international organization of chemical manufacturers, some paid databases, and many others.
Intended Audience
| Report Attribute/Metric | Details |
| Market Size in 2032 | Â Â USD 512.1 Billion |
| Â Â CAGR | Â 10.4% |
| Â Â Base Year | Â Â 2020 |
| Â Â Forecast Period | Â Â 2023-2032 |
| Â Â Historical Data | Â Â 2021 |
| Â Â Forecast Units | Â Â Value (USD Million) |
| Â Â Report Coverage | Â Â Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Â Â Segments Covered | Â Â Type, Product Type, End User |
| Â Â Geographies Covered | Â Â North America, Europe, Asia-Pacific, and Rest of the World |
| Â Â Key Vendors | Â Â Hoffmann-La Roche AG, GlaxoSmithKline, AbbVie Inc., Amgen Inc., Merck & Co. Inc., Bristol-Myers Squibb, Novartis International AG, Eli Lilly and Company, Johnson & Johnson, AstraZeneca plc |
| Â Â Key Market Opportunities | Â Â Increasing cancer population |
| Â Â Key Market Drivers | High effectiveness Less side effects |
Immunotherapy Drugs market Market Highlights:
Frequently Asked Questions (FAQ) :
Immunotherapy Drugs Market is projected to grow at an 10.4% CAGR between 2023-2032.
Europe and the Americas are predicted to dominate the Immunotherapy Drugs Market.
Key competitors in the Immunotherapy Drugs Market include AstraZeneca plc (U.K.), Johnson & Johnson (U.S.), Eli Lilly and Company (U.S.), Novartis International AG (Switzerland), Bristol-Myers Squibb (U.S.), Merck & Co., Inc. (U.S.), Amgen, Inc. (U.S.), AbbVie, Inc. (U.S.), GlaxoSmithKline (U.K.), and F. Hoffmann-La Roche AG (Switzerland).
Rising prevalence of cancer and unavailability of absolute treatment will boost market growth.
Adverse effects and longtime approval may limit market growth.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
